Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Follow-On” Biologics Guidance Will Limit Use Of Data To “Public Domain”

Executive Summary

FDA's upcoming draft guidance on follow-on biologics will allow use of data that are in the public domain only, Center for Drug Evaluation & Research acting Director Steven Galson, MD, told the Schwab Soundview Washington Research Group health care conference May 5

You may also be interested in...



European Biosimilar Guidelines May Leave Room For Regulatory Shortcuts

Marketing authorization for generic biologics may be extrapolated to additional indications approved for the reference product, according to biosimilar guidelines recently released by the European Medicines Agency

European Biosimilar Guidelines May Leave Room For Regulatory Shortcuts

Marketing authorization for generic biologics may be extrapolated to additional indications approved for the reference product, according to biosimilar guidelines recently released by the European Medicines Agency

Follow-On Biologics Will Rely On “Case-By-Case” Approach – Rep. Waxman

FDA's development of a guidance for follow-on versions of insulin and human growth hormone will be a key milestone in demonstrating the agency's ability to implement a "case-by-case" approach to "generic" biologics, Rep. Henry Waxman (D-Calif.) said

Related Content

UsernamePublicRestriction

Register

PS043921

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel